Regulation of gene expression in atherosclerosis: Insights from microarray studies in monocytes/macrophages

Pharmacogenomics

Volumn 13, Issue 4, 2012, Pages 477-495

  Laguna, Juan C ^a,b   Alegret, Marta ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Instituto de Salud Carlos III   (Spain)

Author keywords

atherosclerosis; gene expression profiling; macrophage; microarrays; monocyte

Indexed keywords

APOLIPOPROTEIN E; ATORVASTATIN; CD36 ANTIGEN; HIGH DENSITY LIPOPROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INTERLEUKIN 1BETA; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; OXIDIZED LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOID X RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA;

ABCA1 GENE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CORONARY ARTERY DISEASE; CULTURE TECHNIQUE; CYTOKINE RELEASE; DNA MICROARRAY; DRUG DESIGN; FAMILIAL HYPERCHOLESTEROLEMIA; FOAM CELL; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; LASER CAPTURE MICRODISSECTION; LEUKOCYTE ADHERENCE; LIPID STORAGE; MACROPHAGE; MACROPHAGE ACTIVATION; MICROARRAY ANALYSIS; MONOCYTE; NONHUMAN; OXIDATIVE STRESS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION REGULATION; TRANSCRIPTOMICS; VASCULAR SMOOTH MUSCLE;

ATHEROSCLEROSIS; GENE EXPRESSION REGULATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LIPID METABOLISM; MACROPHAGES; MICROARRAY ANALYSIS; MONOCYTES;

EID: 84857743632     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.9     Document Type: Review

References (156)

1. Seneviratne AN, Sivagurunathan B, Monaco C. Toll-like receptors and macrophage activation in atherosclerosis. Clin. Chim. Acta 413(1-2), 3-14 (2012).
2. Tuomisto TT, Binder BR, Yla-Herttuala S. Genetics, genomics and proteomics in atherosclerosis research. Ann. Med. 37, 323-332 (2005).
3. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 473, 317-325 (2011).
4. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell 145, 341-355 (2011).
5. Badimon L, Storey RF, Vilahur G. Update on lipids, inflammation and atherothrombosis. Thromb. Haemost. 105(Suppl. 1), S34-S42 (2011).
6. Passlick B, Flieger D, Ziegler-Heitbrock HW. Identification and characterization of a novel monocyte subpopulation in human peripheral blood. Blood 74, 2527-2534 (1989).
7. Sunderkotter C, Nikolic T, Dillon MJ et al. Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J. Immunol. 172, 4410-4417 (2004).
8. Huo Y, Xia L. P-selectin glycoprotein ligand-1 plays a crucial role in the selective recruitment of leukocytes into the atherosclerotic arterial wall. Trends Cardiovasc. Med. 19, 140-145 (2009).
9. Johnson JL, Newby AC. Macrophage heterogeneity in atherosclerotic plaques. Curr. Opin. Lipidol. 20, 370-378 (2009).
10. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352, 1685-1695 (2005).
11. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 5, 953-964 (2005).
12. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci. 13, 453-461 (2008).
13. Bouhlel MA, Derudas B, Rigamonti E et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 6, 137-143 (2007).
14. Porcheray F, Viaud S, Rimaniol AC et al. Macrophage activation switching: an asset for the resolution of inflammation. Clin. Exp. Immunol. 142, 481-489 (2005).
15. Mantovani A, Garlanda C, Locati M. Macrophage diversity and polarization in atherosclerosis: a question of balance. Arterioscler. Thromb. Vasc. Biol. 29, 1419-1423 (2009).
16. Tobias P, Curtiss LK. Thematic review series: the immune system and atherogenesis. Paying the price for pathogen protection: toll receptors in atherogenesis. J. Lipid Res. 46, 404-411 (2005).
17. Moore KJ, Freeman MW. Scavenger receptors in atherosclerosis: beyond lipid uptake. Arterioscler. Thromb. Vasc. Biol. 26, 1702-1711 (2006).
18. Kunjathoor VV, Febbraio M, Podrez EA et al. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J. Biol. Chem. 277, 49982-49988 (2002).
19. Manning-Tobin JJ, Moore KJ, Seimon TA et al. Loss of SR-A and CD36 activity reduces atherosclerotic lesion complexity without abrogating foam cell formation in hyperlipidemic mice. Arterioscler. Thromb. Vasc. Biol. 29, 19-26 (2009).
20. Moore KJ, Kunjathoor VV, Koehn SL et al. Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice. J. Clin. Invest 115, 2192-2201 (2005).
21. Kuchibhotla S, Vanegas D, Kennedy DJ et al. Absence of CD36 protects against atherosclerosis in ApoE knock-out mice with no additional protection provided by absence of scavenger receptor A I/II. Cardiovasc. Res. 78, 185-196 (2008).
22. Kruth HS. Sequestration of aggregated low-density lipoproteins by macrophages. Curr. Opin. Lipidol. 13, 483-488 (2002).
23. Kruth HS, Jones NL, Huang W et al. Macropinocytosis is the endocytic pathway that mediates macrophage foam cell formation with native low density lipoprotein. J. Biol. Chem. 280, 2352-2360 (2005).
24. Miller YI, Choi SH, Fang L, Harkewicz R. Toll-like receptor-4 and lipoprotein accumulation in macrophages. Trends Cardiovasc. Med. 19, 227-232 (2009).
25. Howell KW, Meng X, Fullerton DA, Jin C, Reece TB, Cleveland JC Jr. Toll-like receptor 4 mediates oxidized LDL-induced macrophage differentiation to foam cells. J. Surg. Res. 171, e27-e31 (2011).
26. Buhman KF, Accad M, Farese RV Jr. Mammalian acyl-CoA:cholesterol acyltransferases. Biochim. Biophys. Acta 1529, 142-154 (2000).
27. Rothblat GH, Phillips MC. High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr. Opin. Lipidol. 21, 229-238 (2010).
28. Tall AR, Yvan-Charvet L, Terasaka N, Pagler T, Wang N. HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell Metab. 7, 365-375 (2008).
29. Yvan-Charvet L, Ranalletta M, Wang N et al. Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J. Clin. Invest. 117, 3900-3908 (2007).
30. Larigauderie G, Cuaz-Perolin C, Younes AB et al. Adipophilin increases triglyceride storage in human macrophages by stimulation of biosynthesis and inhibition of beta-oxidation. FEBS J. 273, 3498-3510 (2006).
31. Persson J, Degerman E, Nilsson J, Lindholm MW. Perilipin and adipophilin expression in lipid loaded macrophages. Biochem. Biophys. Res. Commun. 363, 1020-1026 (2007).
32. Koltsova EK, Ley K. How dendritic cells shape atherosclerosis. Trends Immunol. 32, 540-547 (2011).
33. Michelsen KS, Wong MH, Shah PK et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in Apolipoprotein E. Proc. Natl Acad. Sci. USA 101, 10679-10684 (2004).
34. Mullick AE, Tobias PS, Curtiss LK. Modulation of atherosclerosis in mice by Toll-like receptor 2. J. Clin. Invest 115, 3149-3156 (2005).
35. Monaco C, Gregan SM, Navin TJ, Foxwell BM, Davies AH, Feldmann M. Toll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis. Circulation 120, 2462-2469 (2009).
36. Stewart CR, Stuart LM, Wilkinson K et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat. Immunol. 11, 155-161 (2010).
37. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352, 1685-1695 (2005).
38. von der Thusen JH, Kuiper J, van Berkel TJ, Biessen EA. Interleukins in atherosclerosis: molecular pathways and therapeutic potential. Pharmacol. Rev. 55, 133-166 (2003).
39. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 27, 519-550 (2009).
40. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117, 3720-3732 (2011).
41. Neumann D, Kollewe C, Martin MU, Boraschi D. The membrane form of the type II IL-1 receptor accounts for inhibitory function. J. Immunol. 165, 3350-3357 (2000).
42. Elhage R, Maret A, Pieraggi MT, Thiers JC, Arnal JF, Bayard F. Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in Apolipoprotein E-deficient mice. Circulation 97, 242-244 (1998).
43. Galea J, Armstrong J, Gadsdon P, Holden H, Francis SE, Holt CM. Interleukin-1 beta in coronary arteries of patients with ischemic heart disease. Arterioscler. Thromb. Vasc. Biol. 16, 1000-1006 (1996).
44. Kirii H, Niwa T, Yamada Y et al. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 23, 656-660 (2003).
45. Rajamaki K, Lappalainen J, Oorni K et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS ONE 5, e11765 (2010).
46. Duewell P, Kono H, Rayner KJ et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357-1361 (2010).
47. Lusis AJ. Atherosclerosis. Nature 407, 233-241 (2000).
48. Libby P. Changing concepts of atherogenesis. J. Intern. Med. 247, 349-358 (2000).
49. Borissoff JI, Spronk HM, Heeneman S, ten Cate H. Is thrombin a key player in the 'coagulation-atherogenesis' maze? Cardiovasc. Res. 82, 392-403 (2009).
50. Croce K, Libby P. Intertwining of thrombosis and inflammation in atherosclerosis. Curr. Opin. Hematol. 14, 55-61 (2007).
51. Shah PK. Mechanisms of plaque vulnerability and rupture. J. Am. Coll. Cardiol. 41, 15S-22S (2003).
52. Manolio TA. Genomewide association studies and assessment of the risk of disease. N. Engl. J. Med. 363, 166-176 (2010).
53. Sivapalaratnam S, Motazacker MM, Maiwald S et al. Genome-wide association studies in atherosclerosis. Curr. Atheroscler. Rep. 13, 225-232 (2011).
54. Teslovich TM, Musunuru K, Smith AV et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466, 707-713 (2010).
55. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270, 467-470 (1995).
56. Farber CR, Lusis AJ. Integrating global gene expression analysis and genetics. Adv. Genet. 60, 571-601 (2008).
57. Walker MS, Hughes TA. Messenger RNA expression profiling using DNA microarray technology: diagnostic tool, scientific analysis or un-interpretable data? Int. J. Mol. Med. 21, 13-17 (2008).
58. Sherlock G. Analysis of large-scale gene expression data. Curr. Opin. Immunol. 12, 201-205 (2000).
59. Kerr G, Ruskin HJ, Crane M, Doolan P. Techniques for clustering gene expression data. Comput. Biol. Med. 38, 283-293 (2008).
60. Werner T. Bioinformatics applications for pathway analysis of microarray data. Curr. Opin. Biotechnol. 19, 50-54 (2008).
61. Gill R, Datta S, Datta S. A statistical framework for differential network analysis from microarray data. BMC Bioinformatics 11, 95 (2010).
62. Diez D, Wheelock AM, Goto S et al. The use of network analyses for elucidating mechanisms in cardiovascular disease. Mol. Biosyst. 6, 289-304 (2010).
63. Engreitz JM, Morgan AA, Dudley JT et al. Content-based microarray search using differential expression profiles. BMC Bioinformatics 11, 603 (2010).
64. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat. Rev. Genet. 10, 57-63 (2009).
65. Malone JH, Oliver B. Microarrays, deep sequencing and the true measure of the transcriptome. BMC Biol. 9, 34 (2011).
66. Ren B, Robert F, Wyrick JJ et al. Genome-wide location and function of DNA binding proteins. Science 290, 2306-2309 (2000).
67. Lee TI, Johnstone SE, Young RA. Chromatin immunoprecipitation and microarray-based analysis of protein location. Nat. Protoc. 1, 729-748 (2006).
68. Lefrancois P, Zheng W, Snyder M. ChIP-Seq using high-throughput DNA sequencing for genome-wide identification of transcription factor binding sites. Methods Enzymol. 470, 77-104 (2010).
69. Espina V, Wulfkuhle JD, Calvert VS et al. Laser-capture microdissection. Nat. Protoc. 1, 586-603 (2006).
70. King C, Guo N, Frampton GM, Gerry NP, Lenburg ME, Rosenberg CL. Reliability and reproducibility of gene expression measurements using amplified RNA from laser-microdissected primary breast tissue with oligonucleotide arrays. J. Mol. Diagn. 7, 57-64 (2005).
71. Badimon L. Atherosclerosis and thrombosis: lessons from animal models. Thromb. Haemost. 86, 356-365 (2001).
72. Holvoet P, Davey PC, De Keyzer D et al. Oxidized low-density lipoprotein correlates positively with toll-like receptor 2 and interferon regulatory factor-1 and inversely with superoxide dismutase-1 expression: studies in hypercholesterolemic swine and THP-1 cells. Arterioscler. Thromb. Vasc. Biol. 26, 1558-1565 (2006).
73. Geeraert B, De Keyzer D, Davey PC, Crombe F, Benhabiles N, Holvoet P. Oxidized low-density lipoprotein-induced expression of ABCA1 in blood monocytes precedes coronary atherosclerosis and is associated with plaque complexity in hypercholesterolemic pigs. J. Thromb. Haemost. 5, 2529-2536 (2007).
74. Holvoet P, Theilmeier G, Shivalkar B, Flameng W, Collen D. LDL hypercholesterolemia is associated with accumulation of oxidized LDL, atherosclerotic plaque growth, and compensatory vessel enlargement in coronary arteries of miniature pigs. Arterioscler. Thromb. Vasc. Biol. 18, 415-422 (1998).
75. Daugherty A. Mouse models of atherosclerosis. Am. J. Med. Sci. 323, 3-10 (2002).
76. Wuttge DM, Sirsjo A, Eriksson P, Stemme S. Gene expression in atherosclerotic lesion of ApoE deficient mice. Mol. Med. 7, 383-392 (2001).
77. NApoli C, de Nigris F, Welch JS et al. Maternal hypercholesterolemia during pregnancy promotes early atherogenesis in LDL receptor-deficient mice and alters aortic gene expression determined by microarray. Circulation 105, 1360-1367 (2002).
78. Tabibiazar R, Wagner RA, Ashley EA et al. Signature patterns of gene expression in mouse atherosclerosis and their correlation to human coronary disease. Physiol. Genomics 22, 213-226 (2005).
79. Tabibiazar R, Wagner RA, Spin JM et al. Mouse strain-specific differences in vascular wall gene expression and their relationship to vascular disease. Arterioscler. Thromb. Vasc. Biol. 25, 302-308 (2005).
80. Karra R, Vemullapalli S, Dong C et al. Molecular evidence for arterial repair in atherosclerosis. Proc. Natl Acad. Sci. USA 102, 16789-16794 (2005).
81. Paul A, Yechoor V, Raja R, Li L, Chan L. Microarray gene profiling of laser-captured cells: a new tool to study atherosclerosis in mice. Atherosclerosis 200, 257-263 (2008).
82. Beer M, Doepping S, Hildner M et al. Laser-capture microdissection of hyperlipidemic/ApoE/mouse aorta atherosclerosis. Methods Mol. Biol. 755, 417-428 (2011).
83. Zadelaar S, Kleemann R, Verschuren L et al. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler. Thromb. Vasc. Biol. 27, 1706-1721 (2007).
84. Wouters K, Shiri-Sverdlov R, van Gorp PJ, van BM, Hofker MH. Understanding hyperlipidemia and atherosclerosis: lessons from genetically modified Apoe and ldlr mice. Clin. Chem. Lab. Med. 43, 470-479 (2005).
85. Bentzon JF, Falk E. Atherosclerotic lesions in mouse and man: is it the same disease? Curr. Opin. Lipidol. 21, 434-440 (2010).
86. Ashley EA, Spin JM, Tabibiazar R, Quertermous T. Frontiers in nephrology: genomic approaches to understanding the molecular basis of atherosclerosis. J. Am. Soc. Nephrol. 18, 2853-2862 (2007).
87. Hiltunen MO, Tuomisto TT, Niemi M et al. Changes in gene expression in atherosclerotic plaques analyzed using DNA array. Atherosclerosis 165, 23-32 (2002).
88. Tuomisto TT, Korkeela A, Rutanen J et al. Gene expression in macrophage-rich inflammatory cell infiltrates in human atherosclerotic lesions as studied by laser microdissection and DNA array: overexpression of HMG-CoA reductase, colony stimulating factor receptors, CD11A/CD18 integrins, and interleukin receptors. Arterioscler. Thromb. Vasc. Biol. 23, 2235-2240 (2003).
89. Seo D, Wang T, Dressman H et al. Gene expression phenotypes of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 24, 1922-1927 (2004).
90. Ashley EA, Ferrara R, King JY et al. Network analysis of human in-stent restenosis. Circulation 114, 2644-2654 (2006).
91. Adams LD, Geary RL, Li J, Rossini A, Schwartz SM. Expression profiling identifies smooth muscle cell diversity within human intima and plaque fibrous cap: loss of RGS5 distinguishes the cap. Arterioscler. Thromb. Vasc. Biol. 26, 319-325 (2006).
92. Sluimer JC, Kisters N, Cleutjens KB et al. Dead or alive: gene expression profiles of advanced atherosclerotic plaques from autopsy and surgery. Physiol. Genomics 30, 335-341 (2007).
93. Eijgelaar WJ, Horrevoets AJ, Bijnens AP, Daemen MJ, Verhaegh WF. Equivalence testing in microarray analysis: similarities in the transcriptome of human atherosclerotic and non-atherosclerotic macrophages. Physiol. Genomics 41(3) 212-223 (2010).
94. Cagnin S, Biscuola M, Patuzzo C et al. Reconstruction and functional analysis of altered molecular pathways in human atherosclerotic arteries. BMC Genomics 10, 13 (2009).
95. Brooks AR, Lelkes PI, Rubanyi GM. Gene expression profiling of human aortic endothelial cells exposed to disturbed flow and steady laminar flow. Physiol. Genomics 9, 27-41 (2002).
96. Brooks AR, Lelkes PI, Rubanyi GM. Gene expression profiling of vascular endothelial cells exposed to fluid mechanical forces: relevance for focal susceptibility to atherosclerosis. Endothelium 11, 45-57 (2004).
97. Shi Y, Tokunaga O. Chlamydia pneumoniae (C. pneumoniae) infection upregulates atherosclerosis-related gene expression in human umbilical vein endothelial cells (HUVECs). Atherosclerosis 177, 245-253 (2004).
98. Kempe S, Kestler H, Lasar A, Wirth T. NF-kappaB controls the global pro-inflammatory response in endothelial cells: evidence for the regulation of a pro-atherogenic program. Nucleic Acids Res. 33, 5308-5319 (2005).
99. Gargalovic PS, Imura M, Zhang B et al. Identification of inflammatory gene modules based on variations of human endothelial cell responses to oxidized lipids. Proc. Natl Acad. Sci. USA 103, 12741-12746 (2006).
100. Suna S, Sakata Y, Sato H et al. Up-regulation of cell adhesion molecule genes in human endothelial cells stimulated by lymphotoxin alpha: DNA microarray analysis. J. Atheroscler. Thromb. 15, 160-165 (2008).
101. Wara AK, Mitsumata M, Yamane T, Kusumi Y, Yoshida Y. Gene expression in endothelial cells and intimal smooth muscle cells in atherosclerosis-prone or atherosclerosis-resistant regions of the human aorta. J. Vasc. Res. 45, 303-313 (2008).
102. Zhang J, Burridge KA, Friedman MH. In vivo differences between endothelial transcriptional profiles of coronary and iliac arteries revealed by microarray analysis. Am. J. Physiol. Heart Circ. Physiol. 295, H1556-H1561 (2008).
103. Feng Y, Yang JH, Huang H et al. Transcriptional profile of mechanically induced genes in human vascular smooth muscle cells. Circ. Res. 85, 1118-1123 (1999).
104. Reeve JL, Stenson-Cox C, O'Doherty A et al. OxLDL-induced gene expression patterns in CASMC are mimicked in ApoE-/-mice aortas. Biochem. Biophys. Res. Commun. 356, 681-686 (2007).
105. Payeli SK, Latini R, Gebhard C et al. Prothrombotic gene expression profile in vascular smooth muscle cells of human saphenous vein, but not internal mammary artery. Arterioscler. Thromb. Vasc. Biol. 28, 705-710 (2008).
106. Van Assche T, Hendrickx J, Crauwels HM et al. Transcription profiles of aortic smooth muscle cells from atherosclerosis-prone and-resistant regions in young apolipoprotein E-deficient mice before plaque development. J. Vasc. Res. 48, 31-42 (2011).
107. Via DP, Pons L, Dennison DK, Fanslow AE, Bernini F. Induction of acetyl-LDL receptor activity by phorbol ester in human monocyte cell line THP-1. J. Lipid Res. 30, 1515-1524 (1989).
108. Llaverias G, Lacasa D, Vazquez-Carrera M, Sanchez RM, Laguna JC, Alegret M. Cholesterol regulation of genes involved in sterol trafficking in human THP-1 macrophages. Mol. Cell Biochem. 273, 185-191 (2005).
109. Llaverias G, Lacasa D, Vinals M et al. Reduction of intracellular cholesterol accumulation in THP-1 macrophages by a combination of rosiglitazone and atorvastatin. Biochem. Pharmacol. 68, 155-163 (2004).
110. Llaverias G, Noe V, Penuelas S et al. Atorvastatin reduces CD68, FABP4, and HBP expression in oxLDL-treated human macrophages. Biochem. Biophys. Res. Commun. 318, 265-274 (2004).
111. Tani M, Kawakami A, Mizuno Y et al. Small dense LDL enhances THP-1 macrophage foam cell formation. J. Atheroscler. Thromb. 18, 698-704 (2011).
112. Kohro T, Tanaka T, Murakami T et al. A comparison of differences in the gene expression profiles of phorbol 12-myristate 13-acetate differentiated THP-1 cells and human monocyte-derived macrophage. J. Atheroscler. Thromb. 11, 88-97 (2004).
113. Qin Z. The use of THP-1 cells as a model for mimicking the function and regulation of monocytes and macrophages in the vasculature. Atherosclerosis doi:10.1016/j. atherosclerosis.2011.09.003 (2011) (Epub ahead of print).
114. Tuomisto TT, Riekkinen MS, Viita H, Levonen AL, Yla-Herttuala S. Analysis of gene and protein expression during monocyte-macrophage differentiation and cholesterol loading-cDNA and protein array study. Atherosclerosis 180, 283-291 (2005).
115. Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J. Immunol. 177, 7303-7311 (2006).
116. Liu H, Shi B, Huang CC, Eksarko P, Pope RM. Transcriptional diversity during monocyte to macrophage differentiation. Immunol. Lett. 117, 70-80 (2008).
117. Persson J, Nilsson J, Lindholm MW. Interleukin-1beta and tumour necrosis factor-alpha impede neutral lipid turnover in macrophage-derived foam cells. BMC Immunol. 9, 70 (2008).
118. Shiffman D, Mikita T, Tai JT et al. Large scale gene expression analysis of cholesterol-loaded macrophages. J. Biol. Chem. 275, 37324-37332 (2000).
119. Mikita T, Porter G, Lawn RM, Shiffman D. Oxidized low density lipoprotein exposure alters the transcriptional response of macrophages to inflammatory stimulus. J. Biol. Chem. 276, 45729-45739 (2001).
120. Daub K, Siegel-Axel D, Schonberger T et al. Inhibition of foam cell formation using a soluble CD68-Fc fusion protein. J. Mol. Med. (Berl.) 88, 909-920 (2010).
121. Fu Y, Luo N, Lopes-Virella MF, Garvey WT. The adipocyte lipid binding protein (ALBP/aP2) gene facilitates foam cell formation in human THP-1 macrophages. Atherosclerosis 165, 259-269 (2002).
122. Levula M, Jaakkola O, Luomala M, Nikkari ST, Lehtimaki T. Effects of oxidized low-and high-density lipoproteins on gene expression of human macrophages. Scand. J. Clin. Lab. Invest. 66, 497-508 (2006).
123. Rosenblat M, Hayek T, Hussein K, Aviram M. Decreased macrophage paraoxonase 2 expression in patients with hypercholesterolemia is the result of their increased cellular cholesterol content: effect of atorvastatin therapy. Arterioscler. Thromb. Vasc. Biol. 24, 175-180 (2004).
124. Hung YC, Hong MY, Huang GS. Cholesterol loading augments oxidative stress in macrophages. FEBS Lett. 580, 849-861 (2006).
125. Hägg D, Englund MC, Jernas M et al. Oxidized LDL induces a coordinated up-regulation of the glutathione and thioredoxin systems in human macrophages. Atherosclerosis 185, 282-289 (2006).
126. Sung HJ, Kim J, Kim Y, Jang SW, Ko J. N-acetyl cysteine suppresses the foam cell formation that is induced by oxidized low density lipoprotein via regulation of gene expression. Mol. Biol. Rep. 39(3), 3001-3007 (2011).
127. Li H, Song Y, Li F et al. Identification of lipid droplet-associated proteins in the formation of macrophage-derived foam cells using microarrays. Int. J. Mol. Med. 26, 231-239 (2010).
128. Chen T, Huang Z, Wang L et al. MicroRNA-125a-5p partly regulates the inflammatory response, lipid uptake, and ORP9 expression in oxLDL-stimulated monocyte/macrophages. Cardiovasc. Res. 83, 131-139 (2009).
129. Hirose K, Iwabuchi K, Shimada K et al. Different responses to oxidized low-density lipoproteins in human polarized macrophages. Lipids Health Dis. 10, 1 (2011).
130. Kalinina N, Agrotis A, Antropova Y et al. Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines. Arterioscler. Thromb. Vasc. Biol. 24, 2320-2325 (2004).
131. Kulkarni AB, Karlsson S. Transforming growth factor-beta 1 knockout mice. A mutation in one cytokine gene causes a dramatic inflammatory disease. Am. J. Pathol. 143, 3-9 (1993).
132. Argmann CA, Van Den Diepstraten CH, Sawyez CG et al. Transforming growth factor-beta1 inhibits macrophage cholesteryl ester accumulation induced by native and oxidized VLDL remnants. Arterioscler. Thromb. Vasc. Biol. 21, 2011-2018 (2001).
133. Aziz H, Zaas A, Ginsburg GS. Peripheral blood gene expression profiling for cardiovascular disease assessment. Genomic Med. 1, 105-112 (2007).
134. Ma J, Dempsey AA, Stamatiou D, Marshall KW, Liew CC. Identifying leukocyte gene expression patterns associated with plasma lipid levels in human subjects. Atherosclerosis 191, 63-72 (2007).
135. Morello F, de Bruin TW, Rotter JI et al. Differential gene expression of blood-derived cell lines in familial combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 24, 2149-2154 (2004).
136. Eurlings PM, van der Kallen CJ, Geurts JM, Kouwenberg P, Boeckx WD, de Bruin TW. Identification of differentially expressed genes in subcutaneous adipose tissue from subjects with familial combined hyperlipidemia. J. Lipid Res. 43, 930-935 (2002).
137. McCaffrey TA, Fu C, Du B et al. High-level expression of Egr-1 and Egr-1-inducible genes in mouse and human atherosclerosis. J. Clin. Invest 105, 653-662 (2000).
138. Harja E, Bucciarelli LG, Lu Y et al. Early growth response-1 promotes atherogenesis: mice deficient in early growth response-1 and apolipoprotein E display decreased atherosclerosis and vascular inflammation. Circ. Res. 94, 333-339 (2004).
139. Albrecht C, Preusch MR, Hofmann G et al. Egr-1 deficiency in bone marrow-derived cells reduces atherosclerotic lesion formation in a hyperlipidaemic mouse model. Cardiovasc. Res. 86, 321-329 (2010).
140. Mosig S, Rennert K, Buttner P et al. Monocytes of patients with familial hypercholesterolemia show alterations in cholesterol metabolism. BMC Med. Genomics 1, 60 (2008).
141. Wibaut-Berlaimont V, Randi AM, Mandryko V, Lunnon MW, Haskard DO, Naoumova RP. Atorvastatin affects leukocyte gene expression in dyslipidemia patients: in vivo regulation of hemostasis, inflammation and Apoptosis. J. Thromb. Haemost. 3, 677-685 (2005).
142. Llaverias G, Pou J, Ros E et al. Monocyte gene-expression profile in men with familial combined hyperlipidemia and its modification by atorvastatin treatment. Pharmacogenomics 9, 1035-1054 (2008).
143. Pou J, Martinez-Gonzalez J, Rebollo A et al. Type II interleukin-1 receptor expression is reduced in monocytes/macrophages and atherosclerotic lesions. Biochim. Biophys. Acta 1811, 556-563 (2011).
144. Pou J, Rebollo A, Piera L et al. Tissue factor pathway inhibitor 2 is induced by thrombin in human macrophages. Biochim. Biophys. Acta 1813, 1254-1260 (2011).
145. Georgieva AM, Cate HT, Keulen ET et al. Prothrombotic markers in familial combined hyperlipidemia: evidence of endothelial cell activation and relation to metabolic syndrome. Atherosclerosis 175, 345-351 (2004).
146. Crawley JT, Goulding DA, Ferreira V, Severs NJ, Lupu F. Expression and localization of tissue factor pathway inhibitor-2 in normal and atherosclerotic human vessels. Arterioscler. Thromb. Vasc. Biol. 22, 218-224 (2002).
147. Pan JJ, Shi HM, Luo XP et al. Recombinant TFPI-2 enhances macrophage apoptosis through upregulation of Fas/FasL. Eur. J. Pharmacol. 654, 135-141 (2011).
148. Puig O, Yuan J, Stepaniants S et al. A gene expression signature that classifies human atherosclerotic plaque by relative inflammation status. Circ. Cardiovasc. Genet. 4(6), 595-604 (2011).
149. Zeller T, Wild P, Szymczak S et al. Genetics and beyond-the transcriptome of human monocytes and disease susceptibility. PLoS ONE 5, e10693 (2010).
150. Yuan Z, Miyoshi T, Bao Y, Sheehan JP, Matsumoto AH, Shi W. Microarray analysis of gene expression in mouse aorta reveals role of the calcium signaling pathway in control of atherosclerosis susceptibility. Am. J. Physiol. Heart Circ. Physiol. 296, H1336-H1343 (2009).
151. Skogsberg J, Lundstrom J, Kovacs A et al. Transcriptional profiling uncovers a network of cholesterol-responsive atherosclerosis target genes. PLoS Genet. 4, e1000036 (2008).
152. Sarov-Blat L, Kiss RS, Haidar B et al. Predominance of a proinflammatory phenotype in monocyte-derived macrophages from subjects with low plasma HDL-cholesterol. Arterioscler. Thromb. Vasc. Biol. 27, 1115-1122 (2007).
153. Gleissner CA, Shaked I, Little KM, Ley K. CXC chemokine ligand 4 induces a unique transcriptome in monocyte-derived macrophages. J. Immunol. 184, 4810-4818 (2010).
154. Hammad SM, Twal WO, Barth JL et al. Oxidized LDL immune complexes and oxidized LDL differentially affect the expression of genes involved with inflammation and survival in human U937 monocytic cells. Atherosclerosis 202, 394-404 (2009).
155. Waehre T, Yndestad A, Smith C et al. Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors. Circulation 109, 1966-1972 (2004).
156. Sinnaeve PR, Donahue MP, Grass P et al. Gene expression patterns in peripheral blood correlate with the extent of coronary artery disease. PLoS ONE 4, e7037 (2009).